GlassScriptPhysician profile
David B Raskin
NPI 1023082112
$5,659.74
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,284 · 2020: $1,747 · 2021: $629.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $814.22 | 2019-2020 | |
| Janssen Biotech, INC. | $674.60 | 2019-2021 | |
| Amgen INC. | $526.79 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $499.93 | 2019-2020 | |
| Astellas Pharma US INC | $330.83 | 2019-2021 | |
| Genentech USA, INC. | $292.02 | 2019-2020 | |
| Seagen INC. | $266.09 | 2019-2020 | |
| Pfizer INC. | $252.60 | 2019-2020 | |
| Pharmacosmos Therapeutics INC. | $247.76 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $223.92 | 2019-2020 | |
| Eisai INC. | $201.77 | 2019 | |
| Incyte Corporation | $176.67 | 2019-2020 | |
| Celgene Corporation | $169.93 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $154.48 | 2019-2020 | |
| Exelixis INC. | $113.78 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $100.33 | 2019-2020 | |
| Lilly USA, LLC | $91.21 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $74.40 | 2019 | |
| Genzyme Corporation | $65.27 | 2019-2020 | |
| Daiichi Sankyo INC. | $57.52 | 2019-2020 | |
| Foundation Medicine, INC. | $50.81 | 2019 | |
| Mylan Institutional INC. | $42.86 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $41.95 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $32.38 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $32.01 | 2019 | |
| Gilead Sciences, INC. | $22.61 | 2019 | |
| Sun Pharmaceutical Industries INC. | $19.55 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $18.19 | 2019 | |
| Puma Biotechnology, INC. | $17.11 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.88 | 2019 | |
| Dova Pharmaceuticals | $16.44 | 2019 | |
| Veracyte, INC. | $14.83 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Raskin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.